Trials / Completed
CompletedNCT06829225
Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002)
A Phase 1, Double-Blind, Placebo-Controlled, Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-7240 in Healthy Chinese Participants.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The goal of this study is to learn about the safety of tulisokibart in healthy participants and what happens to tulisokibart over time when participants receive treatment intravenously versus subcutaneously.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tulisokibart | SC Injection or IV Infusion |
| DRUG | Placebo | Tulisokibart-matched Placebo SC Injection or IV Infusion |
Timeline
- Start date
- 2024-06-13
- Primary completion
- 2024-11-11
- Completion
- 2024-11-11
- First posted
- 2025-02-17
- Last updated
- 2025-02-17
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06829225. Inclusion in this directory is not an endorsement.